Search
Ensartinib
go.drugbank.com/drugs/DB14860ApprovedInvestigational[A273968] Chemically, ensartinib is an aminopyridazine-based, small molecule tyrosine kinase inhibitor (TKI) which inhibits the anaplastic lymphoma kinase (ALK) protein. … Ensartinib was approved by the FDA for adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received an
Categories: P-glycoprotein substratesYohimbine
go.drugbank.com/drugs/DB01392ApprovedInvestigationalVet approvedWithdrawnIt is also alleged to be an aphrodisiac.
Categories: Dopamine D2 Receptor Antagonists, Cytochrome P-450 SubstratesDimazole
go.drugbank.com/drugs/DB13858ApprovedWithdrawnDimazole (diamthazole) is an antifungal. It was withdrawn in Franch in 1972 due to neuropsychiatric reactions.
Abacavir
go.drugbank.com/drugs/DB01048ApprovedInvestigationalAbacavir (ABC) is a powerful nucleoside analog reverse transcriptase inhibitor (NRTI) used to treat HIV and AIDS. Chemically, it is a synthetic carbocyclic nucleoside and is the enantiomer with 1S, 4R absolute configuration on the cyclop...
Mixtures: Triumeq PD, ABACAVIR E LAMIVUDINA DR. REDDY'STechnetium Tc-99m pertechnetate
go.drugbank.com/drugs/DB09314ApprovedInvestigationalTechnetium Tc-99m pertechnetate is a radiopharmaceutical diagnostic agent composed of an oxoanion with the chemical formula TcO4-. … This is normally supplied in a hospital setting through the use of a technetium-99m generator, whereby technetium exits the generator in the form of the pertechnetate ion, TcO4−, which can be extracted
Mixtures: GENERADOR DE SOLUCION INYECTABLE DE PERTECNETATO (99MTC) DE SODIO. 2-50GBQ, TECHNELITE® GENERADOR DE TECNECIO TC 99MBupivacaine
go.drugbank.com/drugs/DB00297ApprovedInvestigationalBupivacaine is a widely used local anesthetic agent.
Mixtures: VAPRINEXT-D, P-Care MCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesAtorvastatin
go.drugbank.com/drugs/DB01076ApprovedInvestigational[A181397, A181403] Atorvastatin was first synthesized in 1985 by Dr. Bruce Roth and approved by the FDA in 1996. … [T571] Unlike other members of the statin group, atorvastatin is an active compound and therefore does not require activation.[A177436]
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesProducts: ATORVASTATINA P-CAREPF-06305591
go.drugbank.com/drugs/DB12106InvestigationalPf 06305591 is under investigation in clinical trial NCT01776619 (Safety and Tolerability Study of Multiple Doses of PF-06305591).
PX-102
go.drugbank.com/drugs/DB15416InvestigationalPX-102 is under investigation in clinical trial NCT01998672 (Multiple Ascending Oral Dose Phase I Study With Px-102).
PF-05105679
go.drugbank.com/drugs/DB15450InvestigationalPF-05105679 is under investigation in clinical trial NCT01393652 (Single Dose, Dose Escalation Healthy Volunteers Study Of PF-05105679).